{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:09:03Z","timestamp":1788851343722,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"DOI":"10.7759\/cureus.115923","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:39:39Z","timestamp":1788849579000},"source":"Crossref","is-referenced-by-count":0,"title":["Bruton Tyrosine Kinase Inhibitor-Based Therapy Versus Rituximab-Containing Regimens for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Sadia","family":"Yousaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uswah","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshbeer Singh","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Mumtaz Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab Mumtaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Awais Bin","family":"Abdul Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek M","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019, 94:1266-87. 10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek M","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al.. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018, 131:2745-60. 10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek M","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al.. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010, 376:1164-74. 10.1016\/s0140-6736(10)61381-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst B","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, et al.. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016, 17:928-42. 10.1016\/S1470-2045(16)30051-1","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst B","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, et al.. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023, 388:1739-54. 10.1056\/NEJMoa2213093","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd JC","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, et al.. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014, 371:213-23. 10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al.. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015, 373:2425-37. 10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020, 395:1278-91. 10.1016\/S0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan A","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, et al.. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016, 17:200-11. 10.1016\/S1470-2045(15)00465-9","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno C","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, et al.. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:43-56. 10.1016\/S1470-2045(18)30788-5","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al.. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023, 388:319-32. 10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02380","article-title":"BRUIN CLL-313: randomized phase III trial of pirtobrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"44","author":"Jurczak W","year":"2026","unstructured":"Jurczak W, Kwiatek M, Czyz J, et al.. BRUIN CLL-313: randomized phase III trial of pirtobrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol. 2026, 44:466-75. 10.1200\/JCO-25-02380","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman JP","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S, et al.. Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025, 43:2538-49. 10.1200\/JCO-25-00166","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia P","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, et al.. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020, 38:2849-61. 10.1200\/JCO.19.03355","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang X","year":"2018","unstructured":"Huang X, Qiu L, Jin J, et al.. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med. 2018, 7:1043-55. 10.1002\/cam4.1337","journal-title":"Cancer Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt TD","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, et al.. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019, 381:432-43. 10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al.. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018, 379:2517-28. 10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam CS","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, et al.. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022, 23:1031-43. 10.1016\/S1470-2045(22)00293-5","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-07006-z","article-title":"Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: a randomized phase 3 Asian study","volume":"105","author":"Li J","year":"2026","unstructured":"Li J, Yi S, Nguyen T, et al.. Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: a randomized phase 3 Asian study. Ann Hematol. 2026, 105:327. 10.1007\/s00277-026-07006-z","journal-title":"Ann Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103707","article-title":"Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group","volume":"91","author":"Quinquenel A","year":"2026","unstructured":"Quinquenel A, Letestu R, Le Garff-Tavernier M, et al.. Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. EClinicalMedicine. 2026, 91:103707. 10.1016\/j.eclinm.2025.103707","journal-title":"EClinicalMedicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2024","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions . Higgins JPT, Thomas J, Chandler J, et al. (ed). Cochrane, London, UK; 2024."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref24","article-title":"WebPlotDigitizer (Version 4.5)","author":"Rohatgi A","year":"2021","unstructured":"Rohatgi A. WebPlotDigitizer (Version 4.5). Automeris LLC, Pacifica, CA, USA; 2021."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney JF","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007, 8:16. 10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref27","unstructured":"Review Manager (RevMan). Version 5.4.1. Copenhagen. The Cochrane Collaboration. (2020). Accessed: August 6, 2026: https:\/\/revman.cochrane.org\/."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger JA","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013, 34:592-601. 10.1016\/j.it.2013.07.002","journal-title":"Trends Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt TD","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, et al.. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022, 140:112-20. 10.1182\/blood.2021014960","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst B","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, et al.. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024, 35:762-8. 10.1016\/j.annonc.2024.06.016","journal-title":"Ann Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato AR","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, et al.. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023, 389:33-44. 10.1056\/NEJMoa2300696","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021, 39:3441-52. 10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir T","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, et al.. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024, 390:326-37. 10.1056\/NEJMoa2310063","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach JA","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, et al.. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017, 35:1437-43. 10.1200\/JCO.2016.70.2282","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour JF","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al.. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023, 142:687-99. 10.1182\/blood.2022018818","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen P","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, et al.. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023, 24:535-52. 10.1016\/S1470-2045(23)00144-4","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/527166-bruton-tyrosine-kinase-inhibitor-based-therapy-versus-rituximab-containing-regimens-for-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:39:40Z","timestamp":1788849580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/527166-bruton-tyrosine-kinase-inhibitor-based-therapy-versus-rituximab-containing-regimens-for-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.115923","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}